Epoetin Beta In Oncology: Examining the Current Evidence

Ludwig, Heinz

doi:10.2217/14796694.2.1.21

Cited by 5 publications

(3 citation statements)

References 90 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epoetin beta mimics the mechanism of action of endogenous erythropoietin and has the same biological activity 50. By binding to the EpoR on erythroid progenitors in the bone marrow, epoetin beta stimulates erythropoiesis, the process by which hematopoietic stem cells differentiate into erythrocytes (Figure 2).…”

Section: Epoetin Betamentioning

confidence: 99%

Epoetin beta for the treatment of chemotherapy-induced anemia: an update

Galli¹,

Ricci²,

Egan³

2015

OTT

View full text Add to dashboard Cite

Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient’s quality of life, should be treated when first diagnosed. Initial trials with ESAs have shown efficacy in improving quality of life and reducing the need for blood transfusions in patients with chemotherapy-induced anemia. However, recent meta-analyses have provided conflicting data on the impact of ESAs on survival and tumor progression. Here we provide an overview of these recent data and review the role of epoetin beta in the treatment of chemotherapy-induced anemia over the past 20 years.

show abstract

Section: Epoetin Betamentioning

confidence: 99%

Epoetin beta for the treatment of chemotherapy-induced anemia: an update

Galli¹,

Ricci²,

Egan³

2015

OTT

View full text Add to dashboard Cite

show abstract

“…The therapeutic development of erythropoietic proteins has had a major impact on the management of cancer-related anaemia [20][21][22]. Several erythropoietic proteins are presently in clinical use: epoetin-α, -β and darbepoetin-α.…”

Section: Erythropoietic Proteinsmentioning

confidence: 99%

Safety considerations for erythropoietin treatment in patients with cancer

Pirker¹

2006

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Cancer-related anaemia, which affects many patients with cancer, can effectively be treated by erythropoietic proteins. Erythropoietic proteins increase haemoglobin levels, reduce the risk for transfusions and also improve the quality of life of patients. When used according to published practice guidelines, these proteins benefit many patients and are generally well tolerated. Important side effects are hypertension and thromboembolic events, either of which occurs in < 10% of the patients. Administration only in anaemic patients, avoidance of target haemoglobin levels > 130 g/l, proper dose adjustments and close monitoring during treatment will ensure the clinical safety of these proteins. However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study.

show abstract

“…Anaemia is a very common complication of cancer [1,2], and it has been shown that improvement of Hb levels in anaemic cancer patients increases quality of life (QoL) [3][4][5][6]. However, anaemia treatment is only given to a minority of anaemic cancer patients [7], mainly due to the high nominal cost of erythropoiesis stimulating agents (ESA).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

et al. 2007

View full text Add to dashboard Cite

Approximately 60% of anaemic cancer patients respond to epoetin treatment. An early marker of response would be valuable in order to avoid ineffective treatment. We have previously shown that beta globin mRNA increases rapidly after epoetin beta treatment of healthy controls. In the present study we have evaluated whether a change of this marker during the first 2 weeks of epoetin treatment could predict later Hb response in anaemic cancer patients. Twenty cancer patients with Hb <11 g/dl received epoetin beta (NeoRecormon) 10,000 IU three times weekly during 6 weeks. Hb, reticulocytes and beta-globin mRNA were followed. The latter was measured quantitatively using PCR via the 5' nuclease assay. Eleven patients responded with a Hb increase of >1 g/dl, nine were nonresponders. All responders increased in beta-globin mRNA within 2 weeks, mean 7.7 x base-line. With a cut-off of an increase of 3 x base-line value, we obtained a specificity of 45% and a sensitivity of 91% for the prediction of a later increase of Hb >1 g/dl. With a cut-off of 4x base-line, the specificity increased to 66%, but the sensitivity decreased to 82%. Beta globin mRNA increases before Hb in all responding patients. However, some non-responding patients also show an increase, and there is a trade-off between specificity and sensitivity as the cut-off level is set at different levels. Compared to reticulocyte count, beta-globin mRNA is more reliable in the individual patient, but the clinical usefulness of the assay needs to be evaluated in further studies.

show abstract

Epoetin Beta In Oncology: Examining the Current Evidence

Cited by 5 publications

References 90 publications

Epoetin beta for the treatment of chemotherapy-induced anemia: an update

Epoetin beta for the treatment of chemotherapy-induced anemia: an update

Safety considerations for erythropoietin treatment in patients with cancer

Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment

Contact Info

Product

Resources

About